When doctors clear a blockage after a heart attack, the sudden rush of blood back into the heart can actually cause a second wave of damage. It's like a fire that was put out, but the water used to extinguish it causes a flood. This project is testing a medicine that calms this internal storm to stop the heart from failing permanently.
Current heart attack treatments save lives but cause 'reperfusion injury' through inflammation, leading to chronic heart failure. This creates a massive burden on healthcare systems with over 26M affected people globally.
A drug candidate, RTP-026, and an approved clinical trial protocol for Phase IIa patient testing.
If you are a drug development firm dealing with the high mortality of ischemic heart disease — this project developed RTP-026 that could reduce post-MI heart failure by >20%. This provides a clear path to a high-demand therapeutic market.
If you are a hospital network dealing with the long-term costs of treating 26M global heart failure patients — this project developed a treatment to resolve inflammation during acute MI. This reduces the risk of patients transitioning into chronic heart failure.
If you are a biotech company dealing with the challenge of reperfusion injury — this project developed an immunomodulating therapeutic. It validates the use of inflammation resolution to protect cardiac tissue.
Based on available project data, the specific cost or price per dose of RTP-026 is not disclosed.
The project is currently in Phase IIa clinical trials; based on available project data, industrial scale-up details are not yet provided.
Based on available project data, the drug candidate RTP-026 is developed by ResoTher Pharma A/S, but specific licensing terms are not listed.
The project runs from 2024-02-01 to 2026-01-31, focusing on Phase IIa and IIb studies, meaning market entry follows these clinical validations.
The project has already finalized and received official approval for the Phase IIa clinical trial protocol from relevant regulatory bodies.
The project is led by a single partner, ResoTher Pharma A/S, a Danish SME. With a 100% industry ratio and no university or research institute partners, the project is lean and focused entirely on the commercial development and clinical validation of the drug candidate.
Contact ResoTher Pharma A/S in Denmark regarding RTP-026 clinical trial partnerships.
Contact us to track the Phase IIb proof of concept results for RTP-026.
